Publications by authors named "Patrice Dubreuil"

Claim this Profile
T
Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression.
Julie Bruneau, Sophie Georgin-Lavialle, Sophia Ladraa, Zakia Belaid, Isabelle Plo, Patrice Dubreuil

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML.
Lise Brault, Edwige Voisset, Mathieu Desaunay, Antonia Boudet, Paraskevi Kousteridou, Patrice Dubreuil

EMBO Mol Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis.
Paula Pernea, Cecile Méni, Julien Rossignol, Hélène Aubert, Sébastien Barbarot, Patrice Dubreuil

JAMA Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1.
Sabina Cisa-Wieczorek, Maria Isabel Hernández-Alvarez, Matilde Parreño, Juan P Muñoz, Elena Bussaglia, Patrice Dubreuil

Exp Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis.
Julien Rossignol, Sophie Georgin-Lavialle, Danielle Canioni, Omer Beganovic, Chantal Brouzes, Patrice Dubreuil

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between eosinophils and IL-5Rα-positive mast cells in nonadvanced systemic mastocytosis.
Guillaume Lefèvre, Jean-Baptiste Gibier, Antonino Bongiovanni, Ludovic Lhermitte, Julien Rossignol, Patrice Dubreuil

J Allergy Clin Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin.
Maël Heiblig, Clément Gourguechon, Philippe Guilpain, Cristina Bulai-Livideanu, Stéphane Barete, Patrice Dubreuil

Am J Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological characterization of liver involvement in systemic mastocytosis.
Julien Rossignol, Danielle Canioni, Achille Aouba, Cristina Bulai-Livideanu, Stéphane Barete, Patrice Dubreuil

Liver Int· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study.
Josquin Moraly, Julien Rossignol, Claire Rouzaud, Thomas Gabas, Hassiba Bouktit, Patrice Dubreuil

Am J Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis.
Hélène Bugaut, Hervé Maillard, Caroline Jacobzone, Naeda Haddad, François Le Pelletier, Patrice Dubreuil

J Am Acad Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes.
Laura Polivka, Marine Madrange, Cristina Bulai-Livideanu, Stéphane Barete, Thomas Ballul, Patrice Dubreuil

J Allergy Clin Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.
Magali Saez-Ayala, Laurent Hoffer, Sébastien Abel, Khaoula Ben Yaala, Benoit Sicard, Patrice Dubreuil

Nat Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation.
Jeoffrey Pelletier, Marielle Balzano, Jérôme Destin, Camille Montersino, Marjorie C Delahaye, Patrice Dubreuil

iScience· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.
Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, Patrice Dubreuil

J Allergy Clin Immunol Pract· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TET2 regulates immune tolerance in chronically activated mast cells.
Riccardo Rigo, Rabie Chelbi, Julie Agopian, Sebastien Letard, Aurélien Griffon, Patrice Dubreuil

JCI Insight· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing diagnostic criteria for mastocytosis in skin biopsies.
Philippe Drabent, Laura Polivka, Julie Agopian, Jean-Paul Duong Van Huyen, Pierre-Alain Thiebaut, Patrice Dubreuil

Histopathology· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness.
Julie Agopian, Quentin Da Costa, Quang Vo Nguyen, Giulia Scorrano, Paraskevi Kousteridou, Patrice Dubreuil

Blood· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma.
Marwa Zerhouni, Anthony R Martin, Nathan Furstoss, Vincent S Gutierrez, Emilie Jaune, Patrice Dubreuil

Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease.
Tengfei Li, Elodie Martin, Yah-Se Abada, Céline Boucher, Aurélia Cès, Patrice Dubreuil

J Alzheimers Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up.
Laura Polivka, Julien Rossignol, Antoine Neuraz, Djiba Condé, Julie Agopian, Patrice Dubreuil

J Allergy Clin Immunol Pract· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
Richard Lemal, Guillemette Fouquet, Louis Terriou, Mélanie Vaes, Cristina Bulai Livideanu, Patrice Dubreuil

J Allergy Clin Immunol Pract· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroinflammatory disorders and mastocytosis: A possible association?
François Rodrigues, Myriam Edjlali, Sophie Georgin-Lavialle, Olivia Chandesris, Stéphane Barete, Patrice Dubreuil

J Allergy Clin Immunol Pract· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Jesus S Mora, Angela Genge, Adriano Chio, Conrado J Estol, Delia Chaverri, Patrice Dubreuil

Amyotroph Lateral Scler Frontotemporal Degener· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the understanding and therapeutic management of mastocytosis.
Julien Rossignol, Laura Polivka, Leila Maouche-Chrétien, Laurent Frenzel, Patrice Dubreuil

F1000Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Ellen Weisberg, Chengcheng Meng, Abigail E Case, Martin Sattler, Hong L Tiv, Patrice Dubreuil

Br J Haematol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis